Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Chronic Hepatitis Delta

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Investigative Site, Anaheim, California, United States

  • University of Louisville, Clinical Trials Unit, Louisville, Kentucky, United States

  • University of Maryland, Institute of Human Virology, Clinical Research Unit, Baltimore, Maryland, United States

  • The New York-Presbyterian Hospital, New York, New York, United States

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, SC Gastroenterologia ed Epatologia, Milan, Italy

  • IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba", Chinsinau, Moldova

  • IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba", Chisinau, Moldova

  • PMSI Clinical Republican Hospital "Timofei Mosneaga", Chisinau, Moldova

  • Institutul National De Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania

  • Fundatia Dr. Victor Babes, Bucharest, Romania

  • Infectious Diseases Institutul National De Boli Infectioase Prof. Matei Bals, Bucharest, Romania

  • Gastromedica S.R.L., Iași, Romania

  • Korea University Ansan Hospital, Ansan-si, South Korea

  • The Catholic University of Korea Bucheon St. Mary's Hospital, Bucheon-si, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea

  • Samsung Medical Center, Seoul, South Korea

  • Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

  • Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan

Study leads
  • Gilead Study Director

    Study Director

    Gilead Sciences